X4 Pharmaceuticals Launches Phase 1b Trial Testing Mavorixafor-Imbruvica Combo for Waldenström’s Macroglobulinemia
News
X4 Pharmaceuticals has launched a Phase 1b trial to assess the safety and tolerability of mavorixafor (X4P-001), in combination with Imbruvica (ibrutinib), for the treatment of people with Waldenström’s macroglobulinemia ... Read more